Who Should Not Take Semaglutide? Clinical Contraindications

Last reviewed: May 16, 2026 Last updated: May 16, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide is not a suitable treatment for everyone. Absolute contraindications include personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN2), or severe pancreatitis. Understanding who should avoid semaglutide is essential for safe, evidence-based weight management.

Beyond absolute contraindications, relative factors—such as gastrointestinal disorders, kidney function, medication interactions, and individual genetic variation in GLP-1 pathway sensitivity—warrant careful provider evaluation. PlexusDx's precision-wellness model integrates clinical assessment with biomarker and genetic insights to help patients and providers make informed decisions about treatment eligibility.

Absolute Medical Contraindications to Semaglutide

Absolute contraindications are conditions where semaglutide use poses unacceptable risk. Personal or family history of medullary thyroid carcinoma (MTC) is a black-box warning; semaglutide may increase MTC risk in animal studies. MEN2 syndrome similarly contraindicates use due to MTC association.

Severe pancreatitis history—particularly acute episodes requiring hospitalization—is an absolute contraindication. GLP-1 agonists can trigger or worsen acute pancreatitis. Additionally, patients with known allergy to semaglutide or any product component should not use this medication. These are non-negotiable safety boundaries regardless of weight loss goals.

Relative Contraindications and Risk Factor Assessment

Relative contraindications require careful provider evaluation but do not automatically exclude semaglutide use. These include diabetic retinopathy, thyroid nodules of undetermined significance, history of pancreatitis, severe gastrointestinal disorders, and moderate to severe kidney disease. Risk-benefit analysis by a qualified provider is essential.

The decision framework below outlines key relative factors that warrant clinical discussion before starting semaglutide, helping patients and providers determine if alternative or cautious-use approaches are appropriate.

Relative Contraindication	Clinical Context and Provider Consideration
Diabetic Retinopathy	Rapid glycemic control may worsen retinopathy; ophthalmology clearance often recommended before starting GLP-1 therapy.
History of Acute Pancreatitis	Non-severe episodes may be manageable with monitoring; severe or recurrent cases warrant avoidance or cautious use with biomarker tracking.
Severe GI Disorders (IBS, Crohn's)	GLP-1 slowing of gastric emptying may exacerbate symptoms; GI specialist consultation recommended.
Moderate-Severe Kidney Disease (eGFR <30)	Limited safety data in advanced renal disease; dose adjustment and frequent monitoring essential; consultation with nephrology advised.
Thyroid Nodules or Abnormal TSH	Baseline thyroid imaging and periodic monitoring recommended; semaglutide not contraindicated but requires close follow-up.
Medications That Increase Pancreatitis Risk	Concurrent use of certain antiretrovirals, corticosteroids, or diuretics may compound pancreatitis risk; medication review essential.

Genetic Variation in GLP-1 Signaling and Treatment Eligibility

Genetic variation in GLP-1 receptor (GLP1R) and related metabolic pathways influences individual responsiveness and safety profiles. Specific variants in GLP1R, GIPR, and FTO genes may affect how an individual's body processes GLP-1 agonists and manages weight regulation. These genetic factors do not determine absolute eligibility but can inform risk-benefit discussions.

PlexusDx's Precision Peptide Genetic Test reveals predispositions in key peptide-signaling variants (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that may help provide context for treatment planning. This genetic insight can support a more personalized conversation with your provider about whether semaglutide aligns with your individual metabolic pathway profile.

Medication Interactions and Polypharmacy Considerations

Semaglutide interacts with several medication classes, making comprehensive medication review essential before initiation. Medications that slow gastric emptying (anticholinergics, some antiemetics) may compound GLP-1 effects and worsen GI side effects. Certain diabetes medications (especially sulfonylureas or insulin) increase hypoglycemia risk when combined with semaglutide.

Patients on oral medications for chronic conditions—including thyroid replacement, blood pressure control, or immunosuppressants—should have these interactions formally reviewed. A qualified healthcare provider must assess whether dose adjustments, medication changes, or closer monitoring are necessary before starting semaglutide. This evaluation is critical for safe polypharmacy management.

Population-Specific Considerations and Provider-Led Decision Making

Certain populations warrant additional caution or alternative approaches. Pregnant or breastfeeding individuals should not use semaglutide due to limited safety data and potential fetal exposure. Adolescents under age 12 lack robust clinical evidence; semaglutide is approved for ages 12+ in some formulations but requires pediatric provider evaluation. Patients with severe dehydration or active infections may require deferral until clinical stability improves.

Ultimately, semaglutide eligibility is a clinical decision made collaboratively between patient and provider. Even when no absolute contraindications exist, individual medical history, biomarker patterns, genetic predispositions, current medications, and treatment goals shape the final decision. Comprehensive medical evaluation before starting any GLP-1 agonist is the standard of care.

How PlexusDx Supports a More Personalized Approach

PlexusDx's genetic testing framework helps contextualize individual variation in GLP-1 and related metabolic pathways. The Precision Peptide Genetic Test measures predispositions in GLP1R, GIPR, FTO, and MC4R variants—insights that may help provide context for how your body's peptide-signaling pathways are wired. This information can support a richer conversation with your provider about semaglutide candidacy and whether your genetic profile suggests strong responsiveness, moderate sensitivity, or factors warranting caution.

It is important to note that genetic predispositions do not predict exact medication response or guarantee treatment success. Your genetic profile reveals tendencies in peptide-signaling pathways, not certainty about semaglutide efficacy or safety in your specific case. Environmental factors, lifestyle, medical history, and concurrent medications equally influence real-world outcomes. The Precision Peptide Genetic Test should be interpreted with a qualified healthcare provider as one piece of a comprehensive clinical assessment.

If you are considering semaglutide and want to understand your individual metabolic and genetic context, the Precision Peptide Genetic Test ($99 as an add-on with a PlexusDx medication order, or $298 standalone) can support that conversation. When combined with your full medical evaluation, this genetic insight may help you and your provider make a more informed decision about whether semaglutide—or an alternative GLP-1 option like our compounded oral or injectable formulations—aligns with your physiology and treatment goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.